We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Swedish Orphan Biovitrum AB (SOBI) NPV

Sell:299.20 SEK Buy:299.40 SEK Change: 6.60 SEK (2.26%)
Market closed |  Prices as at close on 25 July 2024 | Switch to live prices |
Sell:299.20 SEK
Buy:299.40 SEK
Change: 6.60 SEK (2.26%)
Market closed |  Prices as at close on 25 July 2024 | Switch to live prices |
Sell:299.20 SEK
Buy:299.40 SEK
Change: 6.60 SEK (2.26%)
Market closed |  Prices as at close on 25 July 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Swedish Orphan Biovitrum publ AB is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The Company has subsidiaries in Sweden, Denmark, Finland, Norway, United Kingdom and France, among others. On September 9, 2013, the Company acquired the full rights to develop and commercialize Kineret (anakinra) from Amgen, the biotechnology company based in the United States.

Contact details

Tomtebodavagen 23A
171 65
+46 (8) 6972000

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
103.61 billion SEK
Shares in issue:
342.53 million
Stockholm Stock Exchange
Swedish Krona

Key personnel

  • Guido Oelkers
    President, Chief Executive Officer
  • Henrik Stenqvist
    Chief Financial Officer
  • Christine Wesstroem
    Head - Technical Operations
  • Torbjoern Hallberg
    General Counsel and Head of Legal Affairs
  • Lydia Adab-franch
    Chief Medical Officer, Head of Research & Development
  • Duane Barnes
    Head of North America
  • Lena Bjurner
    Head of Human Resources
  • Sofiane Fahmy
    Head of Europe
  • Mahmood Ladha
    Head of Strategic Transformation Operations
  • Norbert Oppitz
    Head of International

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.